12.5 C
Los Angeles
April 12, 2024

Zydus Lifesciences Q4: Consolidated Net Profit Falls 25%, Recommends Dividend

Zydus Lifesciences Q4: Consolidated Net Profit Falls 25%, Recommends Dividend


oi-Renu Baliyan


Zydus Lifesciences Ltd on Thursday declared a 25.36% fall in consolidated net profit to Rs 296.6 crore in the fourth quarter ended March 31, 2023 due to impairment of goodwill of a wholly-owned subsidiary. The company declared a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal. The board of directors of the company declared a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the Annual General Meeting scheduled to be held on August 11, 2023. Check details below:

Zydus Lifesciences Q4: Consolidated total revenue from operations stood at Rs 5,010.6 crore, as against Rs 3,805.6 crore in the corresponding period a year ago, Zydus Lifesciences said in a regulatory filing. Total expenses were higher at Rs 3,961.3 crore, as compared to Rs 3,311.8 crore in the year-ago quarter.

During the quarter, Zydus Lifesciences said it incurred an exceptional item of Rs 594.1 crore as impairment of goodwill by Sentynl Therapeutics Inc, a wholly-owned subsidiary of the group.

Zydus Lifesciences Q4: Consolidated Net Profit Falls 25%, Recommends Dividend

Zydus Lifesciences Declares Dividend: According to the BSE filing of the company, “final dividend of Rs. 6.00/- (@ 600%) per equity share of Re. 1/- each, subject to approval of the shareholders at the AGM and the Record Date as Friday, July 28, 2023, in compliance with regulation 42(1) of the Listing Regulations, to determine the list of shareholders entitled to receive the final dividend for the Financial Year ended on March 31, 2023, payment of which shall be subject to the approval by the members at the AGM.”

Zydus Lifesciences Stock Performance: Last trading price of Zydus Lifesciences is Rs 507.25 per share with intraday fall of 2.28% on BSE. The stock’s 52-week high price is Rs 530.70 apiece and 52-week low price is Rs 329.60 apiece, respectively. The company’s market capitalisation is Rs 51,344.05 crore.

The stock rallied 26% in last 6-months, soared 46%, declined 16% in last 2-years, and jumped 56% in last 3-years.

  • 6 Mid, Large Cap Stocks That Traded Their New 52-Week High Prices
  • Midcap Pharma Stock Trading Near 52-Week High, Sharekhan Assigned “Buy” For 20% Upside
  • Sharekhan Raises Pharma Stock’s Price Target, Foresees Margin Expansion: Buy For Gain
  • 4 Power Sector Stocks & 1 Pharma Stock, Showing Upside, Get Buy, Add Call: HDFC Securities
  • Buy 3 Stocks In January Including 1 PSU Stock Recommended By Ashika Research
  • Buy This 5th Largest Branded Pharma Stock For Target Price Of Rs 445: KR Choksey
  • Buy These 4 Pharma Stocks For Potential Gains Up To 25%, Recommended By Leading Brokerage Firm
  • 2 Stocks To Buy For Gains Up To 83%
  • 3 Board Meetings Lined Up For Buyback, Amalgamation and Bonus For You To Take Note Of
  • Q4: FMCG Co Declares 23% YoY Surge In Profit, Final Dividend & Special Dividend
  • SBI Q4: Net Profit Soars 83%, Declares 1130% Dividend
  • GSK Pharma Q4: Net Profit Declines 89%, Declares Rs 32/Share Dividend

Story first published: Thursday, May 18, 2023, 23:10 [IST]

Related posts

Soil Sampling Program Commences at Parker Dome Lithium Project


ED Seizes Funds Worth Rs 8.26 Crore Of Chinese-Owned Education Company In Bengaluru


Sensex Rallies Over 350 Points In Early Trade


Leave a Comment

Translate »